Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents. PATIENTS AND METHODS: ... non-del(5q) myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents. Response to lenalidomide was ...

    Research Article last updated 07/18/2016 - 10:30am.

  2. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts

    ... Mutations of SF3B1 occur in up to 90% of patients with refractory anaemia with unilineage dysplasia (RARS) and 70% of those with refractory cytopenia with multilineage dysplasia and ring sideroblasts ...

    Research Article last updated 08/15/2016 - 11:29am.

  3. Are Myelodysplastic Syndromes Underdiagnosed in Poland? A Report by the Polish Adult Leukaemia Group

    ... age. The most frequently diagnosed MDS subtype was refractory cytopenia with multilineage dysplasia (RCMD), ...

    Research Article last updated 11/02/2016 - 10:17am.

  4. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes

    ... we conducted a subset analysis limited to patients with refractory anaemia with excess blasts (RAEB). In 2025 HMA-treated ...

    Research Article last updated 10/06/2016 - 11:34am.

  5. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the Europ

    ... not achieve complete remission (CR) and 13% had primary refractory disease. On univariate analysis, outcomes at 3 years were not ... 32%), and fewer patients (10% versus 20%) with primary refractory disease in the CC group than in the HMA group (10% versus 19%, ...

    Research Article last updated 07/18/2016 - 11:22am.

  6. Akiko Shimamura, MD, PhD

    ... 30% of aplastic anemia patients treated with IST are refractory to treatment or develop myelodysplastic syndromes (MDS) and ... 30% of aplastic anemia patients treated with IST are refractory to treatment or develop myelodysplastic syndrome (MDS) and ...

    Grant Recipient last updated 08/19/2015 - 1:32pm.

  7. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

    ... USA and Europe. We enrolled patients with diagnosis of refractory anaemia with excess blasts (RAEB)-1, RAEB-2, RAEB-t, or chronic ...

    Research Article last updated 06/07/2016 - 11:10am.

  8. A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes.

    ... the United States, or in Europe, female in gender, had refractory anemia (RA)/RA with ringed sideroblasts (RARS) or RA ...

    Research Article last updated 04/29/2016 - 12:57pm.

  9. Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia

    ... with acquired severe aplastic anemia (SAA) refractory to immunosuppressive therapy and lacking HLA -matched ... as a salvage therapy for children and adolescents with refractory SAA who lack matched donors. ...

    Research Article last updated 09/04/2014 - 11:22am.

  10. Revisiting use of growth factors in myelodysplastic syndromes

    ... aberrant hematopoiesis and peripheral blood refractory cytopenias. MDS is recognized to be associated with an increased ... patients, and it should be considered for the management of refractory symptomatic cytopenias. G-CSF and EPO in combination can improve ...

    Research Article last updated 07/31/2012 - 12:57pm.